MedChew-1503

**MedChew-1503** is a preclinical cannabinoid-based pharmaceutical delivered via medicated chewing gum (MCG), a novel oral mucosal absorption system that bypasses first-pass liver metabolism for rapid onset and reduced gastric side effects. Developed initially by AXIM Biotechnologies and acquired by Incannex Healthcare (APIRx), it acts as a **CB agonist** targeting cannabinoid receptors to modulate neurological function, primarily for **dementia** with a global addressable market of $23.9B by 2028 (7.9% CAGR). It has FDA Pre-IND clearance and Phase 1 patent grants, positioning it for pain, neurological, and addiction disorders through proprietary formulations backed by 19 granted and 23 pending patents.